Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.32 EUR | +36.75% | 0.00% | 0.00% |
07:17am | Dutch insurer Aegon to launch 200 mln euro share buy-back | RE |
05-14 | Anglo shareholder welcomes proposed strategic revamp | RE |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 11.85B | - | ||
+13.16% | 79.8B | B- | ||
+10.59% | 52B | B+ | ||
+6.04% | 49.71B | B | ||
+21.41% | 46.93B | B+ | ||
+15.32% | 42.95B | B+ | ||
+28.76% | 41.5B | B | ||
+0.65% | 29.55B | B | ||
-3.35% | 29.07B | B- | ||
-9.40% | 27.91B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AGN Stock
- 1AGN Stock
- Ratings Aegon Ltd.